October 10, 2024 11:07 AM EDT
Deals
AI

AI biotechs Re­cur­sion and Ex­sci­en­tia first held deal talks in 2022

Kyle LaHucik

Senior Reporter

When Re­cur­sion Phar­ma­ceu­ti­cals and Ex­sci­en­tia an­nounced plans to merge in Au­gust, it marked the first ma­jor con­sol­i­da­tion in the

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times